Your activity: 2 p.v.

Rifaximin: Drug information

Rifaximin: Drug information
(For additional information see "Rifaximin: Patient drug information" and see "Rifaximin: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Xifaxan
Brand Names: Canada
  • Zaxine
Pharmacologic Category
  • Rifamycin
Dosing: Adult

Note: The 200 mg tablet may not be available in some international markets; consult local product labeling for availability.

Clostridioides difficile infection

Clostridioides difficile infection (second or subsequent recurrence) (alternative regimen) (off-label use):

Note: Rifaximin resistance may be a concern; some experts avoid in patients who have previously received rifamycins, and others do not routinely recommend this regimen (Ref).

Oral: 400 mg 3 times daily for 20 days; administer after a 10-day course of oral vancomycin (Ref).

Hepatic encephalopathy, treatment or prevention

Hepatic encephalopathy, treatment (off-label use) or prevention: Note: Use as an adjunct or alternative to nonabsorbable disaccharides (eg, lactulose) in patients intolerant of or with insufficient response to disaccharides (Ref).

Oral: 550 mg twice daily or 400 mg 3 times daily (Ref). When used for treatment of an acute episode, continue therapy for at least 3 months (Ref).

Irritable bowel syndrome, moderate to severe, without constipation

Irritable bowel syndrome, moderate to severe, without constipation (alternative agent): Note: Reserve for patients, particularly those with bloating, who have failed other therapies (Ref).

Oral: 550 mg 3 times daily for 14 days (Ref).

Pouchitis, acute refractory disease

Pouchitis (post ileal pouch-anal anastomosis), acute refractory disease (off-label use): Oral: 550 mg to 1 g every 12 hours in combination with ciprofloxacin for 28 days (Ref).

Small intestinal bacterial overgrowth

Small intestinal bacterial overgrowth (off-label use): Oral: 550 mg 3 times daily for 14 days (Ref). For patients with methane-predominant bacterial overgrowth, some experts use rifaximin as part of an appropriate combination regimen (Ref).

Travelers’ diarrhea

Travelers’ diarrhea:

Prophylaxis (off-label use): Note: Routine prophylaxis is not recommended. Reserve for select short-term travelers (eg, <2 weeks) at high risk of complications from diarrheal illness. Effectiveness for travelers to South and Southeast Asia may be reduced (Ref).

Oral: 200 mg 1 to 3 times daily for the duration of travel; optimal dose and duration not well established (Ref).

Treatment, moderate to severe (alternative agent): Note: Avoid in patients with fever or bloody diarrhea. Most cases are self-limited and may not warrant antimicrobial therapy (Ref). Some experts reserve antimicrobial therapy for certain high-risk travelers (eg, those with an immunocompromising condition) (Ref).

Oral: 200 mg 3 times daily for 3 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Mild to severe impairment: No dosage adjustment necessary (systemic absorption limited) (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed: No supplemental dose or dosage adjustment necessary (systemic absorption limited) (Ref).

Peritoneal dialysis: Unlikely to be dialyzed: No dosage adjustment necessary (systemic absorption limited) (Ref).

CRRT: No dosage adjustment necessary (systemic absorption limited) (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (systemic absorption limited) (Ref).

Dosing: Hepatic Impairment: Adult

No dosage adjustment necessary. Use with caution in severe impairment (Child-Pugh class C); however, systemic absorption is limited and pharmacokinetic parameters are highly variable.

Dosing: Pediatric

(For additional information see "Rifaximin: Pediatric drug information")

Note: The 200 mg tablet may not be available in some international markets; consult local product labeling for availability.

Clostridioides difficile infection

Clostridioides difficile infection (second or subsequent recurrence):

Children <12 years: Very limited data available: Oral: 15 to 30 mg/kg/day in divided doses 3 times daily for 20 days; usual adult dose: 400 mg/dose; administer after a 10-day course of oral vancomycin (Ref).

Children ≥12 years and Adolescents: Oral: 400 mg 3 times daily for 20 days; administer after a 10-day course of oral vancomycin (Ref).

Inflammatory bowel disease

Inflammatory bowel disease (IBD) (Crohn disease, ulcerative colitis): Limited data available: Children ≥8 years and Adolescents: Oral: 10 to 30 mg/kg/day in divided doses; maximum daily dose: 1,200 mg/day. Dosing based on a retrospective experience of 23 pediatric patients (age range: 8 to 21 years) with IBD flare (Crohn disease: n=12; ulcerative colitis: n=11); patients received rifaximin 400 to 1,200 mg/day (10 to 30 mg/kg/day); improvements in diarrhea and abdominal pain were reported within the first 4 weeks of therapy for the majority of patients (~74%), and within a week in some cases; higher total daily doses (1,200 mg/day vs 400 mg/day) were associated with better symptom control (Ref).

Small intestinal bacterial overgrowth

Small intestinal bacterial overgrowth (SIBO) (eg, associated with irritable bowel syndrome [IBS], short bowel syndrome, chronic abdominal pain): Limited data available; efficacy results variable.

Children 3 to <8 years: Oral: 200 mg 3 times daily for 7 to 14 days (Ref).

Children ≥8 years and Adolescents: Oral: 200 to 550 mg 3 times daily for 7 to 14 days (Ref).

Dosing based on expert recommendations and a prospective study of 50 pediatric patients with SIBO and IBS (age range: 3 to 15 years); results showed 7 days of therapy resulted in improved symptoms and a reduction in bacterial overgrowth based on lactulose breath test (LBT) results (Ref); however, a double-blind placebo-controlled trial in pediatric patients (n=75 including 49 who received rifaximin; age range: 8 to 18 years) with SIBO and chronic abdominal pain showed very low efficacy in normalizing LBT (20% response rate) and treating SIBO compared to placebo at a higher dose of 550 mg 3 times daily for 7 days (Ref). Based on adult experience, some experts use rifaximin as part of an appropriate combination regimen in patients with methane-predominant bacterial overgrowth (Ref).

Travelers' diarrhea, treatment

Travelers' diarrhea, treatment: Note: Avoid use in diarrhea with fever or blood in the stool or diarrhea caused by pathogens other than E. coli; consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment.

Children 3 to 11 years: Limited data available: Oral: 100 mg 4 times daily for up to 5 days has been used in 38 children (age range: 3 to 8 years) to treat infectious diarrhea (Ref).

Children ≥12 years and Adolescents: Oral: 200 mg 3 times daily for 3 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Pediatric

No dosage adjustment necessary. Use with caution in patients with severe impairment (Child-Pugh class C) as systemic absorption does occur and pharmacokinetic parameters are highly variable.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Xifaxan: 200 mg [contains edetate (edta) disodium]

Xifaxan: 550 mg

Generic Equivalent Available: US

No

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 550 mg

Administration: Adult

Oral: Administer with or without food.

Administration: Pediatric

Oral: Administer with or without food.

Use: Labeled Indications

Hepatic encephalopathy, prevention: Reduction in the risk of hepatic encephalopathy recurrence in adults.

Irritable bowel syndrome without constipation: Treatment of moderate to severe irritable bowel syndrome without constipation in adults.

Travelers' diarrhea: Treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in adults and pediatric patients ≥12 years of age.

Limitations of use: Rifaximin should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea caused by pathogens other than E. coli.

Use: Off-Label: Adult

Clostridioides difficile infection (second or subsequent recurrence) (alternative regimen); Hepatic encephalopathy, treatment; Pouchitis (post ileal pouch-anal anastomosis), acute refractory disease; Small intestinal bacterial overgrowth; Travelers’ diarrhea, prophylaxis

Medication Safety Issues
Sound-alike/look-alike issues:

RifAXIMin may be confused with fidaxomicin, rifAMPin.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency of adverse events generally higher following treatment for hepatic encephalopathy (HE). Percentages are presented for HE in adults unless otherwise indicated.

>10%:

Cardiovascular: Peripheral edema (15%)

Gastrointestinal: Nausea (14%; irritable bowel syndrome with diarrhea: 3%)

Hepatic: Ascites (11%)

Nervous system: Dizziness (13%), fatigue (12%)

1% to 10%:

Dermatological: Pruritus (9%), skin rash (5%)

Gastrointestinal: Abdominal pain (9%; upper abdominal pain: 6%), Clostridioides difficile colitis (<5%)

Hematologic & oncologic: Anemia (8%)

Nervous system: Depression (7%), headache (travelers' diarrhea: 10%)

Neuromuscular & skeletal: Arthralgia (6%), increased creatine phosphokinase in blood specimen (<5%), muscle spasm (9%), myalgia (<5%)

Respiratory: Dyspnea (6%), nasopharyngitis (7%)

Miscellaneous: Fever (6%)

Postmarketing (all indications):

Cardiovascular: Flushing

Dermatologic: Exfoliative dermatitis, urticaria

Gastrointestinal: Clostridioides difficile-associated diarrhea

Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction

Contraindications

Hypersensitivity to rifaximin, other rifamycin antibiotics, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions (eg, exfoliative dermatitis, rash, urticaria, flushing, angioneurotic edema, pruritus, anaphylaxis) have occurred; these events have occurred as early as within 15 minutes of drug administration.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including Clostridioides difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Diarrhea: Appropriate use: Avoid use in diarrhea with fever and/or blood in the stool and in the treatment of diarrhea due to pathogens other than Escherichia coli, including Campylobacter jejuni, ShigellaI spp., and Salmonella spp. (efficacy has not been established). Consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment.

• Hepatic impairment: Efficacy for prevention of encephalopathy has not been established in patients with a Model for End-Stage Liver Disease (MELD) score >25; use caution in patients with severe hepatic impairment (Child-Pugh class C).

Dosage form specific issues:

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).

Other warnings/precautions:

• Appropriate use: Not for treatment of systemic infections; <1% is absorbed orally.

Metabolism/Transport Effects

Substrate of CYP3A4 (minor), OATP1A2/SLCO1A2, OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits OATP1A2/SLCO1A2

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Immune Checkpoint Inhibitors: Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors. Risk C: Monitor therapy

Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Risk C: Monitor therapy

P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of RifAXIMin. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Pregnancy Considerations

Adverse events have been observed in some animal reproduction studies. Due to the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the fetus is expected to be low.

Breastfeeding Considerations

It is not known if rifaximin is excreted in human milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Because of the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the nursing infant is expected to be low.

Monitoring Parameters

Hypersensitivity reactions, temperature, blood in stool, change in symptoms; serum ammonia (as clinically indicated) (AASLD [Vilstrup 2014]).

Mechanism of Action

Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase.

Pharmacokinetics

Absorption: Oral:

Travelers' diarrhea: Low

Hepatic encephalopathy: Increased absorption in patients with Child-Pugh class C compared with patients with Child-Pugh class A

Protein binding: Healthy subjects: 67.5%; Hepatic impairment: 62%

Metabolism: Extensive, mainly by CYP3A

Half-life elimination: Healthy subjects: 5.6 hours; IBS without constipation: 6 hours

Time to peak: Healthy subjects and patients with IBS without constipation: ~1 hour

Excretion: Feces (96.6%; primarily as unchanged drug); urine (0.32%)

Pharmacokinetics: Additional Considerations

Hepatic function impairment: The mean AUC in patients with hepatic impairment of Child-Pugh class A, B, and C was 10-, 14-, and 21-fold higher, respectively, compared with that of healthy subjects.

Pricing: US

Tablets (Xifaxan Oral)

200 mg (per each): $11.57

550 mg (per each): $59.51

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Alfa Normix (UA);
  • Arfla (CR, DO, GT, HN, NI, PA, SV);
  • Aximin (BD);
  • Bang Yi (CN);
  • Colidimin (AT);
  • Coloximina (AR);
  • Fatroxim (EG);
  • Faxinorm (DK);
  • Flonorm (CO, CR, DO, GT, HN, MX, NI, PA, SV);
  • Henlix (BD);
  • Idibact (EG);
  • Ifaxim (CO);
  • Lormyx (GR, IL);
  • Normix (BG, CL, CZ, EG, HN, IT, KR, LB, PH, RO, SK, TR, VN);
  • Qian Er Fen (CN);
  • Refero (HK, PT);
  • Ribolac (CL);
  • Rifadom (AR);
  • Rifax (BD);
  • Rifaxin (BD);
  • Rifxima (JP);
  • Spiraxin (ES);
  • Targaxan (BE, GB, IE);
  • Tixtar (ES);
  • Tixteller (BE, NL);
  • Tixtetller (ES);
  • Trencedia (EG);
  • Xifamin (BD);
  • Xifaxan (AU, BB, DE, HK, NL, NO, NZ, PL, SG);
  • Xifaxanta (GB)


For country code abbreviations (show table)
  1. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis. 2005;7(2):182-186. doi:10.1111/j.1463-1318.2004.00746.x [PubMed 15720360]
  2. Based on expert opinion.
  3. Beseghi U, De’Angelis GL. Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children. Eur Rev Med Pharmacol Sci. 1998;2(3-4):131-136. [PubMed 10546408]
  4. Boltin D, Perets TT, Shporn E, et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Ann Clin Microbiol Antimicrob. 2014;13:49. doi: 10.1186/s12941-014-0049-x. [PubMed 25319626]
  5. Bradley JS and Nelson JD, eds. Nelson's Pediatric Antimicrobial Therapy. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.
  6. Chandra R, Kesavan A. Current treatment paradigms in pediatric short bowel syndrome. Clin J Gastroenterol. 2018;11(2):103-112. [PubMed 29280097]
  7. Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr. 2011;52:382-386. [PubMed 21240023]
  8. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142(10):805-812. [PubMed 15897530]
  9. Ferenci P. Hepatic encephalopathy in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 2, 2021.
  10. Ford AC, Moayyedi P, Lacy BE, et al. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109 (suppl 1):S2-S26. doi: 10.1038/ajg.2014.187. [PubMed 25091148]
  11. Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhea. Current Medical Research and Opinion. 1997;14(1):39-45. [PubMed 9524792]
  12. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850-2855. doi: 10.1093/jac/dkr377. [PubMed 21948965]
  13. Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A. Metronidazole or rifaximin for treatment of Clostridium difficile in pediatric patients with inflammatory bowel disease: a randomized clinical trial. Inflamm Bowel Dis. 2017;23(12):2209-2214. [PubMed 29084080]
  14. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13(6):713-718. doi:10.1046/j.1365-2036.1999.00553.x [PubMed 10383499]
  15. Hu Y, Ren J, Zhan M, Li W, Dai H. Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med. 2012;19(6):352-356. doi: 10.1111/j.1708-8305.2012.00650.x. [PubMed 23379704]
  16. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  17. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549 [PubMed 34164674]
  18. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6):846-848. [PubMed 17304459]
  19. Kelly CP, Lamont JT, Bakken JS. Clostridioides (formerly Clostridium) difficile in adults: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 3, 2021a.
  20. Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021b;116(6):1124-1147. doi:10.14309/ajg.0000000000001278 [PubMed 34003176]
  21. LaRocque R, Harris JB. Travelers' diarrhea: Epidemiology, microbiology, clinical manifestations, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 24, 2022.
  22. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003. [PubMed 27528177]
  23. Mas A, Rodés J, Sunyer L, et al; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38(1):51-58. [PubMed 12480560]
  24. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. doi: 10.1093/cid/cix1085. [PubMed 29462280]
  25. Mohammad RA, Regal RE, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother. 2012;46(11):1559-1563. doi: 10.1345/aph.1R146. [PubMed 23092866]
  26. Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2009;49:400-404. [PubMed 19668011]
  27. Pimentel M. Small intestinal bacterial overgrowth: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 27, 2022.
  28. Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci. 2011;56(7):2067-2072. doi: 10.1007/s10620-011-1728-5. [PubMed 21559740]
  29. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165-178. doi:10.14309/ajg.0000000000000501 [PubMed 32023228]
  30. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin. 1995;13(5):274-281. [PubMed 7555036]
  31. Refer to manufacturer's labeling.
  32. Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report. J Travel Med. 2017;24(suppl 1):S57-S74. doi:10.1093/jtm/tax026. [PubMed 28521004]
  33. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25(7):781-786. [PubMed 17373916]
  34. Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome: a preliminary study. European Review for Medical and Pharmacological Sciences. 2013;17:1314-1320. [PubMed 23740443]
  35. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  36. Shen B. Management of acute and chronic pouchitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 2, 2020.
  37. Steffen R, Hill DR, DuPont HL. Traveler's diarrhea: a clinical review. JAMA. 2015;313(1):71-80. doi: 10.1001/jama.2014.17006. [PubMed 25562268]
  38. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735. [PubMed 25042402]
  39. Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 10, 2019.
  40. Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; January 2018.
  41. Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2020.
  42. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219. [PubMed 17555487]
  43. Zaxine (rifaximin) [product monograph]. Montreal, Canada: Lupin Pharma Canada Ltd; February 2019.
Topic 10202 Version 249.0